INOVIQ Limited (ASX:IIQ) has issued an addendum to its Notice of Annual General Meeting dated 23 October 2026, adding a resolution for the election of Andrew Chapman as a Non-Executive Director and withdrawing the re-election resolution for Ms Mary Harney, who is no longer standing for re-election.

Key Points

  • An addendum to the AGM notice adds Item 7 – Resolution 4, seeking shareholder approval for the election of Andrew Chapman as a Non-Executive Director
  • Item 5 – Resolution 2 for the re-election of Ms Mary Harney has been withdrawn as she is no longer standing for re-election
  • The AGM remains scheduled for 10:00am AEDT on Wednesday, 25 November 2026, with no change to the date or time
  • The Board, excluding Mr Chapman, recommends shareholders vote in favour of Resolution 4, with the Chair intending to exercise all available proxies in favour
  • The replacement proxy form must be received by 10:00am AEDT on Monday, 23 November 2026 to be effective

Addendum Details and AGM Resolution Changes

INOVIQ's Board determined to amend and supplement the original Notice of Meeting through an addendum released on 5 November 2026. The addendum introduces Resolution 4 under Item 7, which calls on shareholders to elect Andrew Chapman as a director in accordance with ASX Listing Rule 14.4 and article 6.3 of the Company's Constitution. Simultaneously, the Board withdrew Resolution 2 under Item 5 concerning the re-election of Ms Mary Harney. The addendum is supplemental to the original notice and is to be read in conjunction with it. Definitions from the original Notice of Meeting carry the same meaning in the addendum unless otherwise updated.

Election of Andrew Chapman as Non-Executive Director

Andrew Chapman was appointed as a Non-Executive Director effective 2 November 2026, as announced on 30 October 2026. The filing states Mr Chapman is the Founder of Merchant Funds Management and holds more than 25 years' experience in the financial services industry, with a background in advising biotech companies on capital raisings and financial markets strategy. He currently serves as a Non-Executive Director of Argent BioPharma Ltd (ASX: RGT) and Neurotech International Ltd (ASX: NTI), and as Chairman of Cycliq Group Ltd (ASX: CYQ). Mr Chapman holds a Bachelor of Commerce and a Post Graduate Diploma in Finance and Investment. The Board considers him to be an independent Director.

Proxy Form and Voting Instructions for Shareholders

A replacement proxy form accompanies the addendum. Shareholders who have already lodged the original proxy form and wish to change their votes or cast a vote on the additional Resolution 4 must complete and return the replacement proxy form. Shareholders who have already lodged the original proxy form and do not wish to change their votes on Resolutions 1 and 3, and do not wish to vote on Resolution 4, are not required to take any action. Shareholders who have not yet lodged their original proxy form and wish to vote on Resolutions 1, 3 and 4 should complete and return the replacement proxy form by 10:00am AEDT on 23 November 2026.